BRS2(KC1) - Methyl Donor Pool
(Folate- and betaine-linked input to the methionine/SAM pool)
1. Ambition
Maintain adequate folate- and betaine-linked methyl-group input to sustain homocysteine remethylation and the methionine/SAM resource used across connected mechanisms.
2. Core Nutritional Requirements
- Vitamin B9 (folate)
- Choline
- Betaine
Membership and applicability boundary
The registered constituents are Vitamin B9 (folate), betaine and choline. Folate supplies the carrier/substrate forms used by the folate remethylation route; betaine supplies the alternative methyl donor, and choline can supply betaine. This is a named shared donor-resource network, not an exhaustive inventory of all one-carbon sources or a claim that every constituent supplies every connected reaction (Froese et al., 2019; Obeid, 2013).
Canonical membership establishes identity within this pool. Each PM separately adjudicates Supported upstream supply, Conditional constraint, or an unresolved/not-established relationship. A limiting effect, tissue-wide response or benefit from extra intake cannot be inherited from membership. Vitamin B12 supports the folate reaction as a cofactor and remains outside KC1 membership. SAMe supplementation, creatine and genotype-specific riboflavin remain separately labelled emerging support, not additional registered members.
3. Evidence Base
Summary
This constraint concerns methyl-group supply from folate and betaine for homocysteine remethylation. Folate provides 5-methyltetrahydrofolate, while betaine supplies an alternative donor route and choline can be converted to betaine (Ducker and Rabinowitz, 2017; Zeisel, 2006). Together, these inputs replenish methionine used to produce S-adenosylmethionine (SAM), the body's principal methyl donor, so they form one coherent donor-resource network rather than a list of nearby nutrients (Obeid, 2013).
- Constraint and membership boundary: Vitamin B12 is necessary for methionine synthase but acts as a catalytic cofactor rather than a net methyl-group input; choline's membrane and acetylcholine roles also sit outside this constraint (Froese et al., 2019; Zeisel, 2006).
- Evidence and measurement boundary: Deficiency evidence and plasma-homocysteine responses support remethylation-linked donor constraint, but they do not establish uniform effects on SAM balance, tissue methylation or every connected mechanism (Obeid, 2013; Olthof et al., 2003).
- Biological relevance and provision limitation: Adequate donor availability helps prevent constraint under relevant deficiency or demand states; evidence that provision alters remethylation-related biology does not by itself show that extra intake improves methylation or downstream outcomes in nutrient-replete people (Obeid, 2013; Olthof et al., 2003).
Biological Importance
Folate carries activated one-carbon units. In its 5-methyltetrahydrofolate form it donates the methyl group used to remethylate homocysteine, replenishing methionine for SAM synthesis. Folate insufficiency can therefore constrain the shared donor network, although tissue responses and downstream methylation effects are not uniform.
Supporting Evidence
Ducker and Rabinowitz, 2017 — Reviewed folate-mediated one-carbon transfer, homocysteine remethylation and methionine/SAM biology, establishing the shared resource pathway while distinguishing it from downstream outcomes.
Obeid, 2013 — Reviewed folate deficiency as a cause of hyperhomocysteinaemia, lower SAM and impaired methyl balance, supporting constraint-level membership with tissue and state limitations.
Biological Importance
Choline can be irreversibly oxidised to betaine in liver and kidney. This makes dietary choline an upstream source of methyl groups for BHMT-mediated remethylation, while its separate membrane and acetylcholine roles remain outside this constraint.
Supporting Evidence
Zeisel, 2006 — Reviewed choline as an essential nutrient and major dietary methyl-group source, including its oxidation to betaine and variation in human dietary requirement.
Obeid, 2013 — Synthesised evidence that choline deficiency perturbs methionine formation and hepatic SAM/SAH balance; much of the pool-specific evidence is hepatic and does not establish a universal intake response.
Biological Importance
Betaine is the methyl-donor substrate for BHMT-mediated homocysteine remethylation. This folate-independent route contributes to methionine/SAM availability, especially in liver and kidney and under states in which methyl-donor demand or folate limitation increases reliance on BHMT.
Supporting Evidence
Olthof et al., 2003 — Demonstrated plasma-homocysteine lowering after betaine supplementation in healthy adults, showing that betaine availability can alter remethylation-linked physiology without establishing a universal dietary requirement.
Obeid, 2013 — Reviewed betaine as the BHMT methyl donor and bounded its contribution by organ distribution, metabolic state and interaction with folate and choline.
4. Emerging Biological Supports
This section considers whether an intervention can support methyl-resource availability or reduce a major methyl demand under defined conditions. Candidates do not need to be indispensable nutrients, and they remain separate from the Core Nutritional Requirements above.
Why it is interesting: Supplemental S-adenosylmethionine (SAMe) delivers the downstream methyl donor directly and can raise circulating SAM exposure. This is pharmacological support of methyl-resource availability; it does not restore dietary folate, choline or betaine input or show that those donor routes were deficient (Loehrer et al., 1997; Mischoulon et al., 2012).
Why it remains emerging: Human studies show higher plasma SAM, but often also higher SAH, and do not establish improved intracellular SAM:SAH balance, tissue-specific methylation flux or broad functional benefit. Oral exposure is formulation- and food-dependent, long-term safety is incompletely characterised, and mood activation is a material practical limitation (Yang et al., 2009; Gören et al., 2004).
Evidence interpretation: Increased circulating resource availability is demonstrated. Altered downstream biomarkers are demonstrated, but improved tissue methylation capacity is not. A condition-specific antidepressant response has been reported, but metabolite changes did not predict that response; this does not establish a general methyl-resource functional benefit.
Supporting Evidence
Loehrer et al., 1997 — Exposure: one 400 mg oral dose. Population: 14 healthy adults. Measured endpoints: plasma SAM, SAH, 5-methyltetrahydrofolate, homocysteine and methionine over 24 hours. Results: SAM rose from 38.0 to 361.8 nmol/L and returned toward baseline with a 1.7-hour half-life; SAH and 5-methyltetrahydrofolate also rose transiently, while homocysteine and methionine did not change. Limitations: small, acute and uncontrolled; circulating metabolites do not demonstrate tissue methylation or function.
Yang et al., 2009 — Exposure: 1,000 mg/day enteric-coated oral or intravenous SAMe for five days. Population: 20 healthy Chinese adults, ten per route. Measured endpoints: plasma pharmacokinetics and adverse events. Results: oral exposure was only about 2.1–2.6% of intravenous exposure, with no accumulation or reported adverse events. Limitations: open-label, very short and formulation-specific; no SAM:SAH, methylation-flux or functional endpoint.
Mischoulon et al., 2012 — Exposure: 800–1,600 mg/day oral SAMe or placebo for six weeks alongside a stable serotonin-reuptake inhibitor. Population: a 35-person biomarker subset of adults with major depressive disorder. Measured endpoints: plasma SAM, SAH, homocysteine, methionine, 5-methyltetrahydrofolate and depression response. Results: SAM and SAH increased in the SAMe arm, but metabolite changes were not associated with clinical improvement. Limitations: small disease-specific subset, baseline homocysteine imbalance and plasma rather than tissue measurements.
Gören et al., 2004 — Exposure: oral SAMe titrated to 1,600 mg/day for four weeks. Population: 15 healthy adults. Measured endpoints: serum SAM, homocysteine, selected methylated toxicants and mood ratings. Results: SAM increased without a sustained homocysteine or toxic-metabolite rise; one participant developed a mixed manic state with suicidal ideation that resolved after withdrawal. Limitations: small and unblinded; too short to establish long-term safety.
Decision: Prioritise as a condition-specific, clinically supervised emerging support. SAMe should not be presented as restoration of dietary donor intake. Avoid unsupervised use in bipolar disorder or a history of mania; use with serotonergic medicines or supplements, levodopa/Parkinson's disease, pregnancy, lactation, childhood or immunocompromising conditions requires clinical review. Common tolerability concerns include gastrointestinal upset, headache, anxiety, agitation and insomnia; long-term safety remains uncertain (Sharma et al., 2017).
Why it is interesting: Endogenous creatine synthesis methylates guanidinoacetate using SAM. Supplemental creatine feeds back on this pathway and lowers guanidinoacetate, so it can reduce the precursor supply for a substantial SAM-consuming reaction (Peters et al., 2015).
Why it remains emerging: The demand-reduction action is supported, but whether it improves methyl-resource availability for other pathways or produces a functional benefit through methyl sparing remains unresolved. The best powered human trial did not increase whole-blood SAM, reduce SAH or lower homocysteine on average. Animal homocysteine effects support the biochemical premise but do not establish human methyl redistribution or downstream function (Peters et al., 2015; Stead et al., 2001).
Evidence interpretation: Reduced demand at the creatine-synthesis precursor step is demonstrated in humans. Improved methyl-resource availability, redistribution into other SAM-dependent pathways and a methyl-sparing functional benefit are not demonstrated.
Supporting Evidence
Peters et al., 2015 — Exposure: 3 g/day creatine, placebo, 400 µg/day folic acid or creatine plus folic acid for 12 weeks. Population: Bangladeshi adults; 458 participants in the four relevant groups. Measured endpoints: plasma guanidinoacetate and homocysteine plus whole-blood SAM and SAH. Results: creatine reduced guanidinoacetate by 10.6% while placebo increased it by 3.7%, but creatine did not significantly change homocysteine, SAM or SAH; adding creatine did not improve the folic-acid homocysteine response. Limitations: arsenic-exposed population with frequent folate insufficiency, blood measures are imperfect proxies for hepatic flux, and no direct methyl-redistribution or functional endpoint was measured.
Stead et al., 2001 — Exposure: 0.4% dietary creatine for two weeks. Population: rats. Measured endpoints: renal AGAT activity, plasma homocysteine and related metabolites. Results: AGAT activity fell to 18% of control and plasma homocysteine fell by 27%. Limitations: animal dosing and creatine-synthesis regulation do not establish the same homocysteine or methyl-resource response in humans.
Decision: Retain as an emerging demand-reduction support. Human evidence supports suppression of endogenous creatine synthesis. Whether this improves methyl-resource availability for other pathways or produces a functional benefit through methyl sparing remains unresolved.
Why it is interesting: MTHFR requires flavin adenine dinucleotide derived from riboflavin. In adults homozygous for MTHFR 677TT, a small randomised intervention increased plasma SAM, making riboflavin a specific genotype-conditioned capacity support rather than a generic methyl donor (Rooney et al., 2020).
Why it remains emerging: The evidence is restricted to a small 677TT subgroup and a circulating biomarker. It did not show a clear improvement in SAM:SAH ratio, other one-carbon metabolites or a functional outcome attributable to the SAM change (Rooney et al., 2020).
Evidence interpretation: Increased plasma SAM is demonstrated for the MTHFR 677TT context. Broad resource restoration, improved methylation flux and functional benefit are not demonstrated.
Supporting Evidence
Rooney et al., 2020 — Exposure: 1.6 mg/day riboflavin or placebo for 16 weeks. Population: adults with the MTHFR 677TT genotype, 24 receiving riboflavin and 23 placebo, drawn from earlier blood-pressure trials. Measured endpoints: plasma methionine, SAM, SAH, betaine, choline, cystathionine and homocysteine. Results: SAM increased by 19.5 ± 20.6 nmol/L and cystathionine increased; no other measured one-carbon metabolite showed a significant response. Limitations: small genotype-selected secondary analysis, no tissue methylation measurement and no functional outcome linked to the SAM increase.
Decision: Prioritise narrowly for genotype-conditioned assessment, not as a general KC1 supplement recommendation.
Phosphatidylcholine was not carried forward as a separate candidate because its relevant effect is provision of choline already represented in the core pool. Guanidinoacetate was excluded because conversion to creatine consumes SAM rather than sparing it. Methionine belongs to the separate sulfur-amino-acid constraint, while vitamin B12 is a methionine-synthase cofactor rather than a donor-pool adjunct. Serine, glycine and cysteine were not retained because available evidence concerns pathway participation or transsulfuration/glutathione biology rather than demonstrated support of this named methyl-resource capacity.
5. Connected Mechanisms
Functional Mechanisms
Primary Mechanisms
- BRS2-FM1-PM1 - Folate/B12-Dependent Homocysteine Remethylation
- BRS2-FM1-PM2 - Betaine/BHMT Remethylation
- BRS2-FM1-PM3 - SAMe Synthesis
- BRS2-FM1-PM4 - Methionine Cycle Flux
- BRS2-FM3-PM7 - Phosphatidylcholine Formation
Independently reviewed cross-BRS supply connections
These PM-owned links establish bounded upstream supply, not a uniform constraint on the connected PMs. Individual constituents and limitations are recorded on each PM; membership is not inherited.
- BRS1-FM1-PM3 — Dopaminergic Signalling Regulation — folate, betaine and choline supply the connected methionine/SAM resource route used by COMT; regional neural contribution and limiting effect remain unresolved.
- BRS1-FM1-PM4 — Noradrenergic Signalling — separately adjudicated methionine/SAM supply upstream of COMT; peripheral remethylation is not neuronal BHMT or a proven change in signalling.
- BRS1-FM3-PM7 — Neuronal Membrane DHA Incorporation — individually reviewed folate, betaine and choline supply chains upstream of the methyl-derived LPC-DHA carrier route; donor limitation on adult neuronal DHA incorporation remains unresolved.
- BRS2-FM2-PM5 — Transsulfuration Pathway — conditional hepatic CBS-capacity constraint under combined folate/choline deprivation in rats; individual constituent limitation, causal SAM mediation and net in-vivo flux are not established.
6. Key References
Core Nutritional Requirements
- Ducker and Rabinowitz (2017) — One-Carbon Metabolism in Health and Disease
- Obeid (2013) — Metabolic Burden of Methyl Donor Deficiency
- Zeisel (2006) — Choline Requirements and Methyl-Group Provision
- Froese et al. (2019) — Vitamin B12, Folate and Methionine Remethylation
- Olthof et al. (2003) — Low-Dose Betaine and Plasma Homocysteine
Emerging Biological Supports
- Peters et al. (2015) — Creatine, Guanidinoacetate and Methyl-Cycle Biomarkers
- Stead et al. (2001) — Creatine Provision, Methyl Demand and Homocysteine
- Loehrer et al. (1997) — Oral SAMe and Plasma One-Carbon Metabolites
- Yang et al. (2009) — Oral and Intravenous SAMe Pharmacokinetics
- Mischoulon et al. (2012) — SAMe Bioavailability and One-Carbon Metabolites
- Gören et al. (2004) — SAMe Bioavailability and Tolerability
- Sharma et al. (2017) — SAMe Clinical Safety and Interaction Review
- Rooney et al. (2020) — Riboflavin, MTHFR 677TT and One-Carbon Metabolites